The U.S. Food and Drug Administration (FDA) has granted TikoMed AB’s TM-400 Orphan Drug Designation for the mobilization of stem cells prior to stem cell transplantation treatment.
TM-400 is in development to improve the outcome of hematopoietic stem cell transplantation (HSCT) by increasing the number of cells available for transplantation and thereby the success rate of engraftment and outcome for the patient.
TM-400 can be used for a variety of hematological cancers and other severe diseases, where HSCT is a treatment option, such as multiple myeloma and non-Hodgkins lymphoma.
Release Date: July 26, 2011
Source: TikoMed AB
Filed Under: Drug Discovery